DIAGNOS Accelerates Nationwide Deployment of Its CARA System Solution Licensed by Health Canada Following the Successful Installation of a First Group of Optometry Clinics

Tue, 20 Oct 2026 09:00:00 -0500

BROSSARD, Quebec, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce the successful initial deployment of its newly licensed CARA System software platform (CARA) across its Canadian network.

Following receipt of Health Canada medical device marketing authorization, DIAGNOS rapidly initiated installation of optometry clinics onto the CARA. The Corporation is pleased to report that the first phase of deployment has been successfully executed, validating its onboarding

DIAGNOS Accelerates Nationwide Deployment of Its CARA System Solution Licensed by Health Canada Following the Successful Installation of a First Group of Optometry Clinics

Tue, 20 Oct 2026 09:00:00 -0500

DIAGNOS Accelerates Nationwide Deployment of Its CARA System Solution Licensed by Health Canada Following the Successful Installation of a First Group of Optometry Clinics

Tue, 20 Oct 2026 09:00:00 -0500

DIAGNOS Accelerates Nationwide Deployment of Its CARA System Solution Licensed by Health Canada Following the Successful Installation of a First Group of Optometry Clinics

Tue, 20 Oct 2026 09:00:00 -0500

DIAGNOS Provides an Update on Stock Warrants

Tue, 06 Oct 2026 10:35:00 -0500

BROSSARD, Quebec, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, provides an update on the stock warrants that were exercised and that have expired in the last two months (the “Period”), as well as the outstanding balance.

During the Period, 3,218,333 stock warrants were exercised for gross proceeds of $1,287,333.

During the Period, the following stock warrants have expired.

During the Period, 3,218,333 stock warrants were exercised for gross proceeds of $1,287,333.

During the Period, the following stock warrants have expired.

During the Period, 3,218,333 stock warrants were exercised for gross proceeds of $1,287,333.

During the Period, the following stock warrants have expired.

During the Period, 3,218,333 stock warrants were exercised for gross proceeds of $1,287,333.

During the Period, the following stock warrants have expired.

BROSSARD, Quebec, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that it has submitted a Section 513(g) Request for Information to the U.S. Food and Drug Administration (“FDA”) regarding the classification and applicable regulatory requirements for its CARA System.

The submission follows DIAGNOS’ FDA Pre-Submission filing. DIAGNOS filed this submission to address a specific recommendation received from the FDA. This represents another important step in

DIAGNOS Advances Regulatory Strategy with US FDA Submission for CARA System

Mon, 28 Sep 2026 11:56:00 -0500

The submission follows DIAGNOS’ FDA Pre-Submission filing. DIAGNOS filed this submission to address a specific recommendation received from the FDA. This represents another important step in

DIAGNOS Advances Regulatory Strategy with US FDA Submission for CARA System

Mon, 28 Sep 2026 11:56:00 -0500

The submission follows DIAGNOS’ FDA Pre-Submission filing. DIAGNOS filed this submission to address a specific recommendation received from the FDA. This represents another important step in

DIAGNOS Advances Regulatory Strategy with US FDA Submission for CARA System

Mon, 28 Sep 2026 11:56:00 -0500

The submission follows DIAGNOS’ FDA Pre-Submission filing. DIAGNOS filed this submission to address a specific recommendation received from the FDA. This represents another important step in

Presenting on Emerging Growth Conference 96 Day 1 on September 23; Register to live stream